JP2017525704A5 - - Google Patents

Download PDF

Info

Publication number
JP2017525704A5
JP2017525704A5 JP2017509739A JP2017509739A JP2017525704A5 JP 2017525704 A5 JP2017525704 A5 JP 2017525704A5 JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017509739 A JP2017509739 A JP 2017509739A JP 2017525704 A5 JP2017525704 A5 JP 2017525704A5
Authority
JP
Japan
Prior art keywords
seq
chain
amino acid
acid sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017509739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525704A (ja
JP6742986B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/046173 external-priority patent/WO2016029061A1/en
Publication of JP2017525704A publication Critical patent/JP2017525704A/ja
Publication of JP2017525704A5 publication Critical patent/JP2017525704A5/ja
Application granted granted Critical
Publication of JP6742986B2 publication Critical patent/JP6742986B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017509739A 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤 Active JP6742986B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462039809P 2014-08-20 2014-08-20
US62/039,809 2014-08-20
PCT/US2015/046173 WO2016029061A1 (en) 2014-08-20 2015-08-20 Lyophilized formulations for factor xa antidote

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019165981A Division JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤

Publications (3)

Publication Number Publication Date
JP2017525704A JP2017525704A (ja) 2017-09-07
JP2017525704A5 true JP2017525704A5 (enExample) 2018-09-13
JP6742986B2 JP6742986B2 (ja) 2020-08-19

Family

ID=55351266

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017509739A Active JP6742986B2 (ja) 2014-08-20 2015-08-20 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019165981A Withdrawn JP2019206595A (ja) 2014-08-20 2019-09-12 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2021172975A Active JP7416549B2 (ja) 2014-08-20 2021-10-22 第Ｘａ因子解毒剤の凍結乾燥製剤
JP2023146769A Pending JP2023158199A (ja) 2014-08-20 2023-09-11 第Ｘａ因子解毒剤の凍結乾燥製剤

Country Status (14)

Country Link
US (6) US20160237420A1 (enExample)
EP (2) EP3750556A1 (enExample)
JP (4) JP6742986B2 (enExample)
KR (3) KR102867491B1 (enExample)
CN (2) CN113171447B (enExample)
AU (3) AU2015305413B2 (enExample)
CA (1) CA2961739C (enExample)
DK (1) DK3182993T3 (enExample)
EA (2) EA202091385A3 (enExample)
ES (1) ES2814157T3 (enExample)
IL (2) IL250413B (enExample)
SG (1) SG11201701247RA (enExample)
WO (1) WO2016029061A1 (enExample)
ZA (1) ZA201701764B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
EA202091385A3 (ru) * 2014-08-20 2021-06-30 Портола Фармасьютикалз, Инк. Лиофилизированные составы для антидота фактора ха
CN108883160B (zh) * 2016-02-24 2022-06-28 博尔托拉制药公司 因子xa解毒剂的冻干制剂
EP4588932A3 (en) * 2016-06-17 2025-10-01 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
EP3624828B1 (en) * 2017-05-18 2024-08-07 Merck Sharp & Dohme LLC Pharmaceutical formulation comprising incretin-insulin conjugates
US20210196568A1 (en) * 2018-05-21 2021-07-01 Chugai Seiyaku Kabushiki Kaisha Lyophilized formulation sealed in glass container
CN110760479A (zh) * 2019-05-17 2020-02-07 上海交通大学医学院附属瑞金医院 靶向血小板表达的凝血因子Xa及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2151044A1 (en) 1992-12-15 1994-06-23 Terence K. Brunck Novel inhibitors for factor xa
CA2634663C (en) * 1999-02-22 2009-08-25 University Of Connecticut Novel albumin-free factor viii formulations
US6586574B1 (en) * 1999-08-17 2003-07-01 Nn A/S Stabilization of freeze-dried cake
ES2254385T3 (es) 2000-02-29 2006-06-16 Millennium Pharmaceuticals, Inc. Benzamidas e inhibidores relacionados del factor xa.
US6586584B2 (en) * 2001-01-29 2003-07-01 Becton, Dickinson And Company Sequences and methods for detection of Hepatitis C virus
EP1589949B1 (en) * 2003-01-08 2008-08-13 Novartis Vaccines and Diagnostics, Inc. Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants
RU2440986C2 (ru) 2005-11-08 2012-01-27 Милленниум Фамэсьютикэлс, Инк. СОЛЬ ИНГИБИТОРА ФАКТОРА Ха, СПОСОБ ЕЕ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ЕЕ ОСНОВЕ, СОСТОЯЩИЕ ИЗ НАЗВАННОЙ КОМПОЗИЦИИ ТАБЛЕТКА, КАПСУЛА И ЛЕПЕШКА, СПОСОБ ЛЕЧЕНИЯ ТРОМБОЗА И СПОСОБ ИНГИБИРОВАНИЯ КОАГУЛЯЦИИ ОБРАЗЦОВ КРОВИ
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2193196B1 (en) * 2007-09-28 2016-07-13 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
CN107050437A (zh) 2008-09-03 2017-08-18 奥克塔法马股份有限公司 重组制备的因子viii的新型保护组合物
EP2364165B1 (en) 2008-11-14 2018-01-03 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
LT3604510T (lt) * 2009-03-30 2025-07-10 Alexion Pharmaceuticals, Inc. Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai
JP6163304B2 (ja) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ， インコーポレイテッド 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法
EP2458990B1 (en) * 2009-07-28 2016-03-30 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
WO2011088152A1 (en) * 2010-01-12 2011-07-21 Portola Pharmaceuticals, Inc. Pharmaceutical composition and dosage forms of elinogrel and methods of use thereof
CN103003422B (zh) * 2010-04-20 2015-02-11 奥克塔法马股份有限公司 用于药物蛋白的新型稳定剂
CN103339126B (zh) * 2010-12-03 2016-06-29 博尔托拉制药公司 式(i)化合物的固态形式及其药物组合物、剂型和使用方法
US9683020B2 (en) * 2011-08-01 2017-06-20 Emory University VLPS containing ligands and methods related thereto
US9371522B2 (en) * 2011-09-30 2016-06-21 The Children's Hospital Of Philadelphia Compositions and methods for modulating hemostasis
GB201310946D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Antidote
EA202091385A3 (ru) 2014-08-20 2021-06-30 Портола Фармасьютикалз, Инк. Лиофилизированные составы для антидота фактора ха

Similar Documents

Publication Publication Date Title
JP2017043632A5 (enExample)
EA201892446A1 (ru) Фармацевтическая композиция
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
JP2015231997A5 (enExample)
JP6010155B2 (ja) 組み換え技術によって製造された第ｖｉｉｉ因子のための新規な保護組成物
JP2009540001A5 (enExample)
RU2011127913A (ru) Составы, содержащие антитела
JP7229999B2 (ja) ダプトマイシン製剤
EA200870264A1 (ru) Композиция антител
JP2013079270A5 (enExample)
JP2014514275A5 (enExample)
PL186950B1 (pl) Stabilizowany, nie zawierający albuminy, liofilizowany preparat rFVIII
JP2015091902A5 (enExample)
JP2007332155A5 (enExample)
TWI285106B (en) Stable pharmaceutical composition containing factor VIII
RU2013128277A (ru) СТАБИЛЬНЫЕ ИММУНОГЕННЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Staphylococcus aureus
JP6516829B2 (ja) 第ｖｉｉｉ因子製剤
JP2017510585A5 (enExample)
JP2017141225A5 (enExample)
EA202092926A2 (ru) Лиофилизированные составы, содержащие фактор ix
JP2002249441A (ja) 血液凝固第ｖｉｉ因子を活性化するプロテアーゼ又はそのプロ酵素の安定化された液体製剤
AR093365A1 (es) Formulacion para polipeptidos
JP2021504349A5 (enExample)
MX349837B (es) Composicion de transglutaminasa seca.
JP2013515049A5 (enExample)